product for the treatment of Shigatoxin-producing E. coli (STEC) bacterial infections. Thallion has completed four Phase I clinical trials evaluating the safety of Shigamabs®, which demonstrated that the antibodies are safe and well tolerated when administered both individually and in combination. In February, 2010, Thallion signed a definitive development and license agreement with Laboratoire français du Fractionnement et des Biotechnologies (LFB) for payments of up to €95 million, including a €1.5 million upfront payment. LFB received commercial rights to Shigamabs® for Europe, South America and other territories of strategic interest to LFB, including Russia, Turkey, China, South Korea and Northern African countries, while Thallion retained the rights for North America and the rest of world. The Company initiated a Phase II clinical trial in South America in November 2010 to evaluate Shigamabs® as a treatment for STEC infections. The study will comprise up to 17 clinical sites in Argentina, Chile and Peru.